专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06689869B2 Labeled humanized anti-CD18 antibodies and fragments and kits comprising same 失效
标题翻译：标记的人源化抗CD18抗体和包含其的片段和试剂盒
公开(公告)号：US06689869B2
公开(公告)日：2004-02-10
申请号：US09378967
申请日：1999-08-23
申请人： Herman Waldmann , Martin J. Sims , J. Scott Crowe
发明人： Herman Waldmann , Martin J. Sims , J. Scott Crowe
IPC分类号： C07K1628
CPC分类号： C07K16/2845 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2319/00 , Y10S435/81
摘要： A humanized antibody or antibody fragment having all or part of the CDRs as defined and capable of binding to the human CD18 antigen. The antibody and fragment may be labeled and are useful in a variety of applications, such as in therapy in treating leukocyte mediated conditions such as inhibiting ingress of leukocytes into the lung and other organs and treatment of inflammation. Also provided is a kit for detecting the presence of human CD18 antigen comprising an antibody or fragment of the invention, which is optionally labeled.
摘要翻译：具有定义并能结合人CD18抗原的全部或部分CDR的人源化抗体或抗体片段。抗体和片段可以被标记，并且可用于各种应用，例如用于治疗白细胞介导的病症如抑制白细胞进入肺和其他器官以及治疗炎症的治疗。还提供了用于检测包含本发明的抗体或片段的人CD18抗原的存在的试剂盒，其任选地被标记。

2. 发明授权

US06646109B1 Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit 失效
标题翻译：新型乙酰胆碱门控离子通道受体亚基的克隆和表达
公开(公告)号：US06646109B1
公开(公告)日：2003-11-11
申请号：US09345109
申请日：1999-06-29
申请人： Ana Belen Elgoyhen , David S. Johnson , James Richard Boulter , Stephen Fox Heinemann
发明人： Ana Belen Elgoyhen , David S. Johnson , James Richard Boulter , Stephen Fox Heinemann
IPC分类号： C07K1628
CPC分类号： C07K14/70571 , A01K2217/05
摘要： The present invention provides isolated nucleic acids encoding alpha9 nicotinic acetylcholine receptor subunit and receptor subunit protein encoded thereby. Also provided are vectors containing the invention nucleic acids, host cells transformed therewith, alpha9 nicotinic acetylcholine receptor subunit and functional nicotinic acetylcholine receptors comprising at least one alpha9 subunit expressed recombinantly in such host cells as well as transgenic non-human mammals that express the invention receptor subunit and mutants thereof. Receptors of the invention comprise at least one alpha9 nicotinic acetylcholine subunit and form cationic channels activated by acetylcholine, but blocked by nicotine and muscarine. The invention also provides methods for identifying compounds that modulate the ion channel activity of the functional invention receptors containing at least one invention subunit.
摘要翻译：本发明提供编码α9烟碱型乙酰胆碱受体亚基的分离核酸和由此编码的受体亚基蛋白。还提供了含有本发明的核酸，其转化的宿主细胞，α9烟碱乙酰胆碱受体亚基和功能性烟碱乙酰胆碱受体的载体，其包含在这种宿主细胞中重组表达的至少一个α9亚基以及表达本发明受体的转基因非人哺乳动物亚单位及其突变体。本发明的受体包含至少一个α9烟碱乙酰胆碱亚基，并形成由乙酰胆碱活化但由尼古丁和毒蕈碱胺阻断的阳离子通道。本发明还提供了用于鉴定调节含有至少一个本发明亚单位的功能性受体的离子通道活性的化合物的方法。

3. 发明授权

US06541611B1 LO-CD2b antibody 失效
标题翻译： LO-CD2b抗体
公开(公告)号：US06541611B1
公开(公告)日：2003-04-01
申请号：US09593830
申请日：2000-06-14
申请人： Hervé Bazin , Dominique Latinne , Pierre Gianello
发明人： Hervé Bazin , Dominique Latinne , Pierre Gianello
IPC分类号： C07K1628
CPC分类号： C07K16/2806 , A61K2039/505 , C07K2317/732
摘要： A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.
摘要翻译：结合狒狒和人CD2的单克隆抗体，特别是LO-CD2b抗体。可以使用抗体来预防和抑制人类患者的免疫反应，例如当免疫应答由T细胞或天然杀伤细胞的活化和增殖介导时。

4. 发明授权

US06538110B1 Monoclonal antibodies against the interleukin 2 receptor 失效
标题翻译：针对白细胞介素2受体的单克隆抗体
公开(公告)号：US06538110B1
公开(公告)日：2003-03-25
申请号：US07988945
申请日：1993-03-10
申请人： Ulrich Weidle , Eberhard Russmann , Klaus-Peter Hirth , Tiberiu Diamantstein , Brigitte Kaluza
发明人： Ulrich Weidle , Eberhard Russmann , Klaus-Peter Hirth , Tiberiu Diamantstein , Brigitte Kaluza
IPC分类号： C07K1628
CPC分类号： C07K16/468 , A61K38/00 , C07K16/2866
摘要： The invention concerns an antibody composition which inhibits the binding of interleukin 2 to its high affinity receptor and contains (1) monoclonal antibodies against the &agr; chain of the interleukin 2 receptor and (2) monoclonal antibodies against the &bgr; chain of the interleukin 2 receptor, as well as a pharmaceutical agent which contains the antibody composition according to the present invention.
摘要翻译：本发明涉及抑制白细胞介素2与其高亲和力受体结合的抗体组合物，并且含有（1）针对白细胞介素2受体的α链的单克隆抗体和（2）针对白细胞介素2受体的β链的单克隆抗体，以及含有本发明的抗体组合物的药剂。

5. 发明授权

US06437100B1 DNA encoding a human histamine receptor of the H3 subtype 有权
标题翻译：编码H3亚型人体组胺受体的DNA
公开(公告)号：US06437100B1
公开(公告)日：2002-08-20
申请号：US09642514
申请日：2000-08-21
申请人： Timothy W. Lovenberg , Mark Erlander , Arne Huvar , Jayashree Pyati
发明人： Timothy W. Lovenberg , Mark Erlander , Arne Huvar , Jayashree Pyati
IPC分类号： C07K1628
CPC分类号： C07K14/723 , C12N2799/026
摘要： DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
摘要翻译：已经克隆并表征了编码人组胺H3受体的DNA。重组蛋白能够形成生物活性组胺H3受体蛋白。 cDNA已经在产生活性重组蛋白的重组宿主细胞中表达。重组蛋白也从重组宿主细胞中纯化。此外，重组宿主细胞用于建立识别受体活性调节剂的方法，并鉴定受体调节剂。

6. 发明授权

US06329510B1 Anti-CCR1 antibodies and methods of use therefor 失效
标题翻译：抗CCR1抗体及其使用方法
公开(公告)号：US06329510B1
公开(公告)日：2001-12-11
申请号：US09239938
申请日：1999-01-29
申请人： Shixin Qin , Walter Newman , Nasim Kassam
发明人： Shixin Qin , Walter Newman , Nasim Kassam
IPC分类号： C07K1628
CPC分类号： C07K16/2866 , A61K2039/505
摘要： The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 1 (CCR1) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR1 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
摘要翻译：本发明涉及与哺乳动物（例如人）CC趋化因子受体1（CCR1）或受体的一部分结合并阻断配体与受体的结合的抗体或其功能片段。本发明还涉及抑制携带哺乳动物CCR1的细胞与其配体的相互作用的方法，以及在研究，治疗，预防和诊断方法中使用抗体和片段。

7. 发明授权

US06316601B1 Antibodies specific for &bgr;6 integrins 有权
标题翻译： β6整合素特异性抗体
公开(公告)号：US06316601B1
公开(公告)日：2001-11-13
申请号：US09365695
申请日：1999-08-02
申请人： Xiaozhu Huang , Dean Sheppard
发明人： Xiaozhu Huang , Dean Sheppard
IPC分类号： C07K1628
CPC分类号： C07K16/2839 , A01K2217/05 , A01K2217/075 , A61K38/39 , C07K14/70546 , C07K2317/76
摘要： Antibodies specific for &bgr;6 integrins are provided.
摘要翻译：提供了针对β6整联蛋白的抗体

8. 发明授权

US06770745B2 Common gamma chain blocking agents 有权
标题翻译：常见的γ链阻断剂
公开(公告)号：US06770745B2
公开(公告)日：2004-08-03
申请号：US09824286
申请日：2001-04-02
申请人： Linda C. Burkly , Christopher D. Benjamin , Catherine Hession
发明人： Linda C. Burkly , Christopher D. Benjamin , Catherine Hession
IPC分类号： C07K1628
CPC分类号： C07K14/7155 , A61K38/00 , A61K39/00 , C07K16/2866 , C07K2319/00
摘要： The invention relates to antibodies which specifically bind to the gc chain of cytokine receptors, as well as to cell lines which produce such antibodies, pharmaceutical compositions, and methods of treating immunological diseases by treating patients with such antibodies.
摘要翻译：本发明涉及特异性结合细胞因子受体的gc链的抗体以及产生这种抗体的细胞系，药物组合物和通过用这种抗体治疗患者来治疗免疫疾病的方法。

9. 发明授权

US06713609B1 Monoclonal antibodies to type I interferon receptor 失效
标题翻译： I型干扰素受体的单克隆抗体
公开(公告)号：US06713609B1
公开(公告)日：2004-03-30
申请号：US09056461
申请日：1998-04-07
申请人： Anan Chuntharapai , Kyung Jin Kim , Richard B. Love , Ji Lu
发明人： Anan Chuntharapai , Kyung Jin Kim , Richard B. Love , Ji Lu
IPC分类号： C07K1628
CPC分类号： G01N33/6866 , C07K16/2866 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N2333/56
摘要： Anti-IFNAR1 monoclonal antibodies with neutralizing activities against the anti-viral cytopathic effects of various type I interferons are provided.
摘要翻译：提供具有针对各种I型干扰素的抗病毒细胞病变作用的中和活性的抗IFNAR1单克隆抗体。

10. 发明授权

US06696549B1 Antibodies to the cytoplasmic domain of the thrombopoietin receptor 有权
标题翻译：血小板生成素受体的细胞质结构域的抗体
公开(公告)号：US06696549B1
公开(公告)日：2004-02-24
申请号：US09652037
申请日：2000-08-31
申请人： Jerry Spivak , Alison Moliterno
发明人： Jerry Spivak , Alison Moliterno
IPC分类号： C07K1628
CPC分类号： G01N33/80 , G01N33/5091 , G01N33/56966 , G01N33/57484 , G01N2333/91205
摘要： Impaired TPO-mediated platelet protein tyrosine phosphorylation was consistently observed in patients with polycythemia vera (PV) as well as those with idiopathic myelofibrosis (IMF), in contrast to patients with essential thrombocytosis, chronic myelogenous leukemia, secondary erythrocytosis, iron deficiency anemia, hemochromatosis or normal volunteers. Moreover, the platelet TPO receptor, Mpl, was not detectable by immunoblotting with an antibody to the extracellular domain, by chemical crosslinking of TPO to the surface of platelets, or by flow cytometry using an antibody to the extracellular domain, in 34 of 34 PV patients and also in 13 of 14 IMF patients. Impaired TPO-induced protein tyrosine phosphorylation in PV and IMF platelets was uniformly associated with markedly reduced or absent expression of the extracellular domain of Mpl. Thus the reduced detectablility of Mpl by these methods can be used a marker of PV and IMF. The abnormality appears to distinguish PV from other forms of erythrocytosis and may be involved in the platelet function defect associated with PV.
摘要翻译：与患有原发性血小板增多症，慢性骨髓性白血病，继发性红细胞增多症，缺铁性贫血，血色素沉着症的患者相比，真性红细胞增多症（PV）患者以及特发性骨髓纤维化（IMF）患者一致观察到TPO介导的血小板蛋白酪氨酸磷酸化受损或正常志愿者。此外，血小板TPO受体Mpl不能通过用细胞外结构域的抗体进行免疫印迹，通过TPO与血小板表面的化学交联，或者通过流式细胞术，使用34个PV中的34个中的34个患者以及14名IMF患者中的13名。在PV和IMF血小板中受损的TPO诱导的蛋白酪氨酸磷酸化与Mpl细胞外结构域的显着降低或缺失表达均匀相关。因此，通过这些方法降低Mpl的可检测性可以用于PV和IMF的标记。异常似乎将PV与其他形式的红细胞增多症区分开来，并且可能参与与PV相关的血小板功能缺陷。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式